
    
      Phase 3, placebo controlled, double-blind, randomized, clinical study to determine safety,
      tolerability and efficacy of pulsed inhaled nitric oxide (iNO) versus placebo as add-on
      therapy in subjects with pulmonary arterial hypertension (PAH) who remain symptomatic on
      approved PAH monotherapy or combination approved PAH therapy and long term oxygen therapy
      (LTOT). (Part 1 and Part 2)
    
  